U.S. markets close in 26 minutes
  • S&P 500

    3,926.65
    +45.28 (+1.17%)
     
  • Dow 30

    31,986.23
    +448.88 (+1.42%)
     
  • Nasdaq

    13,585.70
    +120.50 (+0.89%)
     
  • Russell 2000

    2,276.13
    +44.81 (+2.01%)
     
  • Crude Oil

    63.19
    +1.52 (+2.46%)
     
  • Gold

    1,798.70
    -7.20 (-0.40%)
     
  • Silver

    27.89
    +0.20 (+0.73%)
     
  • EUR/USD

    1.2165
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • GBP/USD

    1.4130
    +0.0016 (+0.11%)
     
  • USD/JPY

    105.8900
    +0.6530 (+0.62%)
     
  • BTC-USD

    48,889.37
    +2,058.93 (+4.40%)
     
  • CMC Crypto 200

    979.25
    -35.67 (-3.51%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    29,671.70
    -484.33 (-1.61%)
     

Recap: Amphastar Pharmaceuticals Q3 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share increased 50.00% year over year to $0.15, which beat the estimate of $0.14.

Revenue of $83,431,000 up by 4.11% year over year, which missed the estimate of $91,260,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 06, 2020

View more earnings on AMPH

Time: 12:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/4feqnxzx

Technicals

Company's 52-week high was at $22.69

Company's 52-week low was at $12.32

Price action over last quarter: Up 2.43%

Company Overview

Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.